{
  "company_name": "Opal Bidco SAS (Opella)",
  "legal_entity": "Opal Bidco SAS",
  "alternate_names": [
    "Opella",
    "Sanofi Consumer Health",
    "OHG"
  ],
  "sector": "Healthcare - OTC Pharmaceuticals",
  "geography": "France",
  "last_updated": "2026-01-21",
  "data_source": "Debtwire",
  "ratings": {
    "moodys": {
      "rating": "NR",
      "outlook": null
    },
    "sp": {
      "rating": "NR",
      "outlook": null
    },
    "note": "New LBO - ratings likely to be assigned. TLB repriced to E+325bps suggests BB-range credit"
  },
  "overview": {
    "business_description": "Over-the-counter pharmaceutical manufacturer producing and distributing self-care products across 100+ consumer health brands globally. Carved out from Sanofi and acquired by CD&R in April 2025. Brands include Dulcolax, Allegra, Essentiale, and other OTC medicines.",
    "business_positives": [
      "Very low distress score of 7 - performing credit",
      "ALL debt trading ABOVE PAR (100-103)",
      "Strong CD&R sponsorship (50% stake)",
      "Successfully repriced TLB to E+325bps/S+300bps (Oct 2025)",
      "Leading global OTC/consumer health platform",
      "100+ established consumer health brands",
      "Recurring revenue from essential healthcare products",
      "Large scale - ~$9bn acquisition value",
      "Former Sanofi division with proven track record"
    ],
    "fatal_flaw": "New LBO with significant leverage (~$8.4bn debt). Limited standalone track record post-separation. OTC market competitive with J&J, GSK, Haleon. Integration/carve-out execution risk.",
    "ownership": "Private - PE-owned. Clayton Dubilier & Rice (CD&R) Fund XII owns 50% stake since April 2025.",
    "recent_news": "Repriced EUR 1.7bn and USD 3.8bn TLB to E+325bps/S+300bps at par (Oct 2025). Original TLB priced at E+350bps/S+325bps and SSN at 5.5%/6.5% (Mar-Apr 2025). $9.07bn acquisition completed Apr 2025."
  },
  "quick_assessment": {
    "total_debt": 8400,
    "cash_on_hand": null,
    "revolver_available": 1100,
    "debt_due_one_year": 0,
    "cffo": null,
    "interest_expense": null,
    "ebitda": null,
    "note": "New LBO - limited standalone financials. Large debt quantum for carve-out."
  },
  "key_ratios": {
    "debt_to_ebitda": null,
    "net_debt_to_ebitda": null,
    "note": "Financials not yet publicly reported post-separation. Leverage likely 5-6x based on LBO sizing."
  },
  "debt_capitalization": [
    {
      "instrument": "EUR 1bn Revolving Credit",
      "amount": 1100,
      "maturity": "Oct 2031",
      "coupon": null,
      "price": 99.94,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "USD 4bn Term Loan B",
      "amount": 4000,
      "maturity": "2032",
      "coupon": "S+300bps",
      "price": 100.81,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured First Lien",
      "note": "Repriced Oct 2025 from S+325bps"
    },
    {
      "instrument": "EUR 2bn Term Loan B",
      "amount": 2200,
      "maturity": "2032",
      "coupon": "E+325bps",
      "price": 101.13,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured First Lien",
      "note": "Repriced Oct 2025 from E+350bps"
    },
    {
      "instrument": "USD 1bn Sr Secd Notes",
      "amount": 1000,
      "maturity": "2032",
      "coupon": "6.5%",
      "price": 102.56,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 1bn Sr Secd Notes",
      "amount": 1100,
      "maturity": "2032",
      "coupon": "5.5%",
      "price": 102.89,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    }
  ],
  "maturity_schedule": {
    "year_1": 0,
    "year_2": 0,
    "year_3": 0,
    "year_4": 0,
    "year_5": 0,
    "year_6": 1100,
    "thereafter": 8300,
    "note": "Well-termed maturity profile - RCF 2031, TLB/Notes 2032. No near-term maturities."
  },
  "recent_issuance": [
    {
      "date": "Oct 2025",
      "instrument": "TLB Repricing",
      "pricing": "E+325bps / S+300bps (from E+350bps / S+325bps)"
    },
    {
      "date": "Apr 2025",
      "instrument": "EUR 5.2bn TLB (euro/dollar)",
      "pricing": "E+350bps / S+325bps"
    },
    {
      "date": "Apr 2025",
      "instrument": "EUR 2.25bn SSN (euro/dollar)",
      "pricing": "5.5% / 6.5%"
    }
  ],
  "transaction_overview": {
    "deal_value": 9070,
    "acquirer": "Clayton Dubilier & Rice (CD&R)",
    "seller": "Sanofi",
    "completion_date": "Apr 2025",
    "lead_banks": [
      "Mizuho",
      "BNP Paribas",
      "Credit Agricole",
      "Goldman Sachs",
      "JP Morgan"
    ],
    "legal_advisors": [
      "DLA Piper",
      "Pinheiro Neto"
    ]
  },
  "credit_opinion": {
    "recommendation": "OVERWEIGHT",
    "summary": "OHG/Opella is a strong performing credit with very low distress score (7). This is CD&R's carve-out of Sanofi's consumer health division - a leading global OTC pharma platform with 100+ established brands. All debt trading above par (100-103) with successful TLB repricing to E+325bps/S+300bps in Oct 2025 demonstrating strong market confidence. While leverage is elevated for a new LBO (~$8.4bn debt), the business has stable recurring revenue from essential healthcare products. Well-termed maturity profile with no maturities until 2031-2032. Strong sponsor backing from CD&R.",
    "key_risks": [
      "New LBO with elevated leverage (~5-6x estimated)",
      "Carve-out/separation execution risk",
      "Limited standalone financial track record",
      "OTC market competition (J&J, GSK/Haleon, Reckitt)",
      "Private PE ownership - limited transparency",
      "Large debt quantum ($8.4bn)",
      "Healthcare regulatory risk",
      "Generic/private label competition in OTC"
    ],
    "key_catalysts": [
      "Rating assignment - likely BB-range given pricing",
      "First standalone financial reporting",
      "EBITDA growth from synergies/optimization",
      "Further TLB repricing if spreads tighten",
      "Deleveraging from cash flow generation",
      "Bolt-on M&A to expand brand portfolio"
    ]
  },
  "distress_indicators": {
    "debtwire_distress_score": 7,
    "lifecycle_status": "Performing credit",
    "trading_signals": "All debt at 100-103 (above par). Successful repricing to E+325bps/S+300bps shows strong market support. Very low distress score for new LBO."
  }
}